PT  - JOURNAL ARTICLE
AU  - Berna Kömürcüoglu
AU  - Esra Korkmaz
AU  - Cenk Kirakli
AU  - Bilge Salik
TI  - Locally advanced stage nonsmallcell cancers explode in hyperglisemia: A new prognostic factors?
AID  - 10.1183/13993003.congress-2016.PA2847
DP  - 2016 Sep 01
TA  - European Respiratory Journal
PG  - PA2847
VI  - 48
IP  - suppl 60
4099  - http://erj.ersjournals.com/content/48/suppl_60/PA2847.short
4100  - http://erj.ersjournals.com/content/48/suppl_60/PA2847.full
SO  - Eur Respir J2016 Sep 01; 48
AB  - In this study, chemo- radiotherapy (CRT) the hyperglycemia of patients with NSCLC applied survival, disease free survival and investigated the effect of local-regional control.Material and method: Between 2010-2015 years, 71 cases who implemented concurrent chemo-radiotherapy (CRT) were included in the study. Fasting blood glucose levels diagnostic process, including CRT process and dividing the period up to the first three periodic recurrences after CRT, determined by the highest value retrospectively evaluated on the basis of highest levels.Results: 52 patients (73%), squamous cell carcinoma(SCC), 19 (27%) had adenocarcinoma and 58% Applied KT number was 2 (2-2) and dose of RT was 63 Gy (63-63), respectively. Median survival was 19 months , overall survival was 9 months, respectively. Total survival before CRT both fasting glucose level 110 mg / dl with both 126 mg / dL in patients less than was even longer (log-rank p = 0.03 and 0.023)in SCCIn the subgroup analysis, it was observed that these differences are apparent in the SCC (glucose<110 mg / dL to Log-rank p= 0.009 and Glucose <126 mg / dL for log-rank p = 0.017).In SCC patients during CRT glucose 135 mg / dL (106-191), while the adenocarcinoma group, 114 mg / dL (96-142), respectively (p =0.025). Glucose value to repeat the process until after CRT of local recurrence cases with 138 mg / dL (119-228), while the value in patients without recurrence 111 mg / dL (99-164), respectively (p= 0.022).Results: High fasting blood glucose values during the CRT may still pose a risk for local recurrence, especially in patients with squamous cell carcinoma.